Korean prosecutors raid SillaJen over suspected insider trading by Amirah Al Idrus Thursday, August 29, 2019 Prosecutors raided SillaJen on Wednesday after allegations that an executive used undisclosed information to sell stocks.
Phase 3 trial of Transgene's oncolytic virus halted for futility by Nick Paul Taylor Friday, August 2, 2019 The setback sent Transgene's share price downward and added to doubts about the effectiveness of oncolytic viruses.
EuroBiotech: More Articles of Note by Nick Paul Taylor Thursday, May 16, 2019 In our EuroBiotech roundup this week, uniQure posts gene therapy data, Modus’ sickle cell trial fails and TreeFrog raises cash for cell therapy R&D.
AstraZeneca ups oncolytic virus activity with Transgene deal by Nick Paul Taylor Thursday, May 2, 2019 AstraZeneca is paying $10 million upfront to get Transgene to apply its oncolytic virus expertise and technologies to the development of five assets.
Merck KGaA in Transgene cancer vaccine-checkpoint inhibitor test tie-up by Ben Adams Wednesday, October 12, 2016 German Merck has inked another combo trial deal, this time with its Pfizer-backed experimental PD-L1 candidate avelumab set to be used alongside Transgene’s cancer vax TG4001.
